Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis
Non-randomised trial
OA: bronze
CC0
⤵ 9 in-corpus citations
AI-generated summary
Elevated CA 19-9 and chromogranin A, in addition to CA 125, were detected in benign gynecologic tumors like endometriosis and leiomyomas, with some patients showing only CA 19-9 or CgA elevation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma. Both of these benign tumors are known to be at risk of developing into cancer. During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both. In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma. Many patients only had elevated CA 19-9 or CgA; the elevation of CA 125 was not detected. It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (10)
- CA-125 and uterine leiomyomas via openalex
- CA 125 in benign gynecological conditions via openalex
- Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors via openalex
- Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy via openalex
- Role of endometriosis in cancer and tumor development via openalex
- W2055296381 via openalex
- W2075196920 via openalex
- W2132793138 via openalex
- W1996591824 via openalex
- W7073960379 via openalex
Cited by (9)
- Systemic thromboembolism including multiple cerebral infarctions with middle cerebral artery occlusion caused by the progression of adenomyosis with benign gynecological tumor: a case report 2021
- Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report 2018
- Blood biomarkers for the non-invasive diagnosis of endometriosis 2016
- CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics 2014
- Avaliação do CA-125 e do CD-23 solúvel em pacientes com endometriose pélvica 2011
- Non-invasive diagnosis of endometriosis with proteomic technologies 2011
- Uterus-Like Ovarian Mass with Elevated Serum Levels of CA 19-9 and CA 125: A Case Report and Review of the Literature 2010
- Avaliação do CA-125 e do CD-23 solúvel em pacientes com endometriose pélvica 2010
- Identifying biomarkers of endometriosis using serum protein fingerprinting and artificial neural networks 2008
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T21:04:24.806248+00:00
License: CC0
· commercial use OK